3m_istock-458291485_wellesenterprises

wellesenterprises / iStockphoto.com

21 June 2017Americas

BIO 2017: Section 101 raises fundamental policy question, says 3M

The perceived problem with 35 USC section 101 is a “fundamental question of national innovation policy”, claimed Kevin Rhodes, vice president and chief IP counsel at multinational conglomerate 3M.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Lanham Act: brand owners’ current weapon of choice

11 June 2020 As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

BIO 2018: Stop bashing the patent system, says USPTO director

5 June 2018 “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More on this story

Lanham Act: brand owners’ current weapon of choice

11 June 2020 As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

BIO 2018: Stop bashing the patent system, says USPTO director

5 June 2018 “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More on this story

Lanham Act: brand owners’ current weapon of choice

11 June 2020 As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

BIO 2018: Stop bashing the patent system, says USPTO director

5 June 2018 “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent